ProCE Banner Activity


Expert Strategies for Managing Adverse Events With Combination Immune Checkpoint Inhibitor/Targeted Therapy

Text Module

In this module developed for the multidisciplinary care team, Eric Jonasch, MD, and Kathleen Moore, MD, discuss optimal strategies for identifying and managing adverse events associated with immune checkpoint inhibitors as single agents and in combination with VEGF-targeted agents or PARP inhibitors.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: May 25, 2023

Expiration: May 24, 2024

No longer available for credit.



Eric Jonasch

Eric Jonasch, MD

Professor, Department of GU Medical Oncology
UT MD Anderson Cancer Center 
Houston, Texas

Kathleen N Moore

Kathleen N Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Cancer Therapeutics Co-Director
Stephenson Cancer Center at the University of Oklahoma
Oklahoma City, Oklahoma

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Eisai, Merck Sharp & Dohme, LLC, and Regeneron Pharmaceuticals, Inc.



Merck Sharp & Dohme, LLC

Regeneron Pharmaceuticals, Inc

Target Audience

This educational program is intended for oncologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with cancer using immunotherapy.

Program Learning Goal

The goal of this program is to improve the knowledge, confidence, competence, and performance of learners in identifying and selecting individualized management techniques for adverse events associated with immune checkpoint inhibitor combination therapies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply evidence-based practices for the monitoring and management of irAEs associated with immuno-oncology combination therapies

  • Discern between immune-related and targeted therapy–associated AEs to identify proper management approaches

  • Improve communication and care coordination with nononcology specialists and with patients/caregivers to manage irAEs

  • Apply current recommendations for therapy adjustments given known treatment-related AEs


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Eric Jonasch, MD

Professor, Department of GU Medical Oncology
UT MD Anderson Cancer Center 
Houston, Texas

Eric Jonasch, MD: consultant/advisor/speaker: Aveo, Aravive, Calithera, DAVA Oncology, Eisai, Exelixis, Genentech, Ipsen, Merck, NiKang, Takeda; researcher: Arrowhead, Merck, NiKang.

Kathleen N Moore, MD, MS

Virginia Kerley Cade Chair in Developmental Therapeutics
Deputy Director
Cancer Therapeutics Co-Director
Stephenson Cancer Center at the University of Oklahoma
Oklahoma City, Oklahoma

Kathleen Moore, MD: consultant/advisor/speaker: Aadi, Aravive, Alkermes, AstraZeneca, Blueprint Pharma, Caris, Clovis, Eisai, Genentech/Roche, GlaxoSmithKline, Hengrui, Immunogen, Lilly, Mereo, Merck, Mersana, Myriad, Novartis, Onconova, OncXerna, Panavance, VBL Therapeutics, Verastem.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive credit, learners must follow these steps during the period from May 25, 2023, through May 24, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.00 contact hours.

Continuing Pharmacy Education
CCO designates this continuing education activity for 1.00 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-23-141-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.